An interventional study of Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence and Prophylactic use of metronidazole pills (500 mg) in Bacterial Vaginosis, sponsored by Janneke van de Wijgert. Completed. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by Janneke van de Wijgert · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A pilot randomized controlled clinical trial of intermittent use of two different vaginal lactobacilli-containing probiotics, and oral metronidazole, to prevent bacterial vaginosis recurrence.
This is a pilot study to prepare for larger clinical trials. Sixty-eight HIV-negative, non-pregnant, sexually active women aged 18-45 with bacterial vaginosis (BV, by modified Amsel criteria and/or Nugent score) and/or Trichomonas vaginalis (TV, on wet mount or by culture) will be treated using oral metronidazole for 7 days. After successful treatment, and when they are free of vaginal candidiasis, other curable sexually transmitted infections (STIs) and urinary tract infection (UTI)), they will be randomised to 4 different vaginal microbiome (VMB) maintenance interventions (17 per group) within 3 days of completing oral metronidazole treatment: 1) Behavioral 'vaginal practices cessation and safer sex' counselling only (control); 2) Behavioral counselling plus 500mg metronidazole pills twice per week for two months; 3) Behavioral counselling plus Ecologic Femi vaginal capsule, once per day for 5 days immediately after oral metronidazole treatment followed by thrice weekly, for two months; 4) Group 4: Behavioral counselling plus Gynophilus vaginal tablet, once every 4 days for two months. Vaginal probiotic use may be ceased temporarily during menstruation. Participants will be asked to adhere to the interventions for 2 months, and VMB assessments will take place before (screening and enrolment visits), during (Day 7, Month 1 and Month 2 visits), and after the interventions (Month 6 visit).
240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.
This study's enrollment of 68 is below the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.
Browse Vaginosis, Bacterial studies →Janneke van de Wijgert is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Negative control group: After initial treatment for BV/TV, no intervention.
Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
Drug: Prophylactic use of metronidazole pills (500 mg)
After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
Biological: Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence
After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
Biological: Vaginal Lcr35-containing probiotic for prevention of BV recurrence
Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
Also known as: Ecologic Femi+ vaginal capsule
Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
Also known as: Tricozole
Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
Also known as: Gynophilus LP vaginal tablet
Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria
Modified Amsel criteria positive is at least 2 of 3 of the following positive: clue cells, vaginal pH, whiff test. Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as denominator of each incidence rate.
Time frame: 2 months (intervention period)
Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)
The Nugent score is a scale from 0-10 based on visualisation of three different bacterial morphotypes on a Gram stained slide, but in the incidence rates, the variable was used as a binary variable: BV present (Nugent score 7-10) or absent (Nugent score 0-6). Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as the denominator for each incidence rate.
Time frame: 2 months (intervention period)
Trichomonas Vaginalis (TV) Incidence by Culture
A swab was inoculated into an InPouch culture pouch, specifically designed for TV growth. The pouch was checked daily for five days to detect growth. The results was positive when growth detected and negative when no growth detected on the fifth day. Intent-to-treat (ITT) analyses, using person-years (PY) at risk as the denominator for each incidence rate.
Time frame: 2 months (intervention period)
Vaginal Candidiasis Incidence by Wet Mount Microscopy
A wet mount is a smear of vaginal fluid on a microscopy slide, which is examined under a microscope. Yeasts are visible without staining. The definition of vaginal candidiasis was any yeast visible on the wet mount. Symptomatic vaginal candidiasis was considered a safety outcome because treatment of bacterial vaginosis often results in vaginal candidiasis. Intent-to-treat (ITT) analysis with person-years (PY) at risk as the denominator of all incidence rates.
Time frame: 6 months: 2 months intervention period plus 4 months after intervention cessation
Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration
The vaginal microbiota sequencing results are exploratory and full data can be found in a manuscript on the BioRxiv preprint server. The most important outcome is the concentration of Lactobacillus genus in vaginal samples taken at the end of the intervention period (M2 visit).
Time frame: 2 months (intervention period)
Feasibility/Acceptability of Vaginal Probiotic Use by Structured Face-to-face Interview
Full results have been submitted for publication. Adherence was measured at D7, M1, and M2 visits, and a summary measure over the entire period was calculated (available for women using oral metronidazole, Ecologic Femi+, or Gynophilus LP). After the 2-month intervention period, women using vaginal probiotics (Ecologic Femi+ or Gynophilus LP) were asked structured questions about their experiences with product use.
Time frame: 2 months (intervention period)
The target population was women at high risk of urogenital infections living in Kigali, Rwanda. Recruitment activities were implemented by study staff with the help of Community Mobilizers, who were selected due to their strong connections with high-risk women in Kigali. They helped staff organize recruitment meetings in relevant communities.
| Milestone | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Started | 17 | 17 | 17 | 17 |
| Day 7 visit | 17 | 17 | 17 | 16 |
| Month 1 visit | 17 | 17 | 17 | 16 |
| Month 2 visit | 17 | 16 | 17 | 16 |
| Month 6 visit | 17 | 16 | 16 | 15 |
| Completed | 17 | 16 | 16 | 15 |
| Not completed | 0 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 |
Modified Amsel criteria positive is at least 2 of 3 of the following positive: clue cells, vaginal pH, whiff test. Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as denominator of each incidence rate.
| Incidence: events per PY at risk | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria | 7.53 (4.28 to 13.26) | 2.04 (0.66 to 6.31) | 3.36 (1.51 to 7.48) | 3.35 (1.26 to 8.92) |
The Nugent score is a scale from 0-10 based on visualisation of three different bacterial morphotypes on a Gram stained slide, but in the incidence rates, the variable was used as a binary variable: BV present (Nugent score 7-10) or absent (Nugent score 0-6). Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as the denominator for each incidence rate.
| Incidence: events per PY at risk | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10) | 10.18 (5.48 to 18.92) | 1.41 (0.35 to 5.62) | 3.58 (1.61 to 7.96) | 5.36 (2.41 to 11.93) |
A swab was inoculated into an InPouch culture pouch, specifically designed for TV growth. The pouch was checked daily for five days to detect growth. The results was positive when growth detected and negative when no growth detected on the fifth day. Intent-to-treat (ITT) analyses, using person-years (PY) at risk as the denominator for each incidence rate.
| Incidence: events per PY at risk | Control Arm | Metronidazole Arm | Ecologic Femi+ Arm | Gynophilus LP Arm |
|---|---|---|---|---|
| Trichomonas Vaginalis (TV) Incidence by Culture | 1.10 (0.35 to 3.41) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
A wet mount is a smear of vaginal fluid on a microscopy slide, which is examined under a microscope. Yeasts are visible without staining. The definition of vaginal candidiasis was any yeast visible on the wet mount. Symptomatic vaginal candidiasis was considered a safety outcome because treatment of bacterial vaginosis often results in vaginal candidiasis. Intent-to-treat (ITT) analysis with person-years (PY) at risk as the denominator of all incidence rates.
| Incidence: events per PY at risk | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Vaginal Candidiasis Incidence by Wet Mount Microscopy | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
The vaginal microbiota sequencing results are exploratory and full data can be found in a manuscript on the BioRxiv preprint server. The most important outcome is the concentration of Lactobacillus genus in vaginal samples taken at the end of the intervention period (M2 visit).
| Lactobacillus log10 copies/microliter | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration | 3.86 (2.53 to 5.19) | 5.21 (4.27 to 6.14) | 5.30 (4.97 to 5.63) | 4.68 (3.55 to 5.81) |
Full results have been submitted for publication. Adherence was measured at D7, M1, and M2 visits, and a summary measure over the entire period was calculated (available for women using oral metronidazole, Ecologic Femi+, or Gynophilus LP). After the 2-month intervention period, women using vaginal probiotics (Ecologic Femi+ or Gynophilus LP) were asked structured questions about their experiences with product use.
| Participants | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|
| Perfect (100%) overall adherence | 12 | 10 | 8 |
| Overall adherence ≥90% | 14 | 15 | 11 |
| Overall adherence ≥80% | 15 | 17 | 13 |
| Probiotic insertion as "very comfortable" | — | 17 | 15 |
| Probiotic insertion became easier over time | — | 17 | 15 |
Collected over 6 months: during the 2-month intervention period and up to 4 months after intervention cessation. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 0/17 (0%) | 0/17 (0%) | 2/17 (11.8%) |
| Oral Metronidazole | 0/17 (0%) | 1/17 (5.9%) | 2/17 (11.8%) |
| Ecologic Femi+ | 0/17 (0%) | 1/17 (5.9%) | 2/17 (11.8%) |
| Gynophilus LP | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
| Event | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Typhoid feverInfections and infestations | 0/17 | 1/17 | 0/17 | 0/17 |
| Malaria during pregnancyInfections and infestations | 0/17 | 0/17 | 1/17 | 0/17 |
| Event | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP |
|---|---|---|---|---|
| Genital burningReproductive system and breast disorders | 0/17 | 0/17 | 1/17 | 2/17 |
| Genital itchingReproductive system and breast disorders | 2/17 | 2/17 | 2/17 | 2/17 |
| Pain during sexReproductive system and breast disorders | 1/17 | 2/17 | 0/17 | 1/17 |
| Burning when passing urineRenal and urinary disorders | 0/17 | 0/17 | 0/17 | 1/17 |
| Lower abdominal painGeneral disorders | 0/17 | 0/17 | 0/17 | 1/17 |
| Unusual vaginal dischargeReproductive system and breast disorders | 1/17 | 0/17 | 0/17 | 0/17 |
| Sores in the genital and/or anal areaReproductive system and breast disorders | 0/17 | 0/17 | 0/17 | 1/17 |
| Age, Categorical(Participants) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 17 | 17 | 17 | 68 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| Median | 29 (24 to 36) | 30 (27 to 34) | 33 (28 to 35) | 31 (27 to 35) | 31 (27 to 35) |
| Sex: Female, Male(Participants) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| Female | 17 | 17 | 17 | 17 | 68 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| African (Rwandan) | 17 | 17 | 17 | 17 | 68 |
| Region of Enrollment(Participants) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| Rwanda | 17 | 17 | 17 | 17 | 68 |
| Exchanged sex for money/goods in past month(Participants) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| Count of participants | 17 | 14 | 15 | 17 | 63 |
| Sex partners in the past month(sex partners) | Control | Oral Metronidazole | Ecologic Femi+ | Gynophilus LP | Total |
|---|---|---|---|---|---|
| Median | 5 (3 to 20) | 5 (2 to 10) | 3 (2 to 15) | 3 (2 to 20) | 5 (2 to 18) |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Feb 2016, 8 months.
Results were first posted in Jul 2019, 3 years 4 months after primary completion.
Of 52 interventional studies with no phase under Vaginosis, Bacterial, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 56. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janneke van de Wijgert